New Delhi: Catalent Inc cut its full-year net revenue and profit forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to ...
Alessandro Maselli; President, CEO & Director; Catalent, Inc. Paul Surdez; VP of IR; Catalent, Inc. Ricky Hopson; Interim CFO; Catalent, Inc. David Howard Windley; MD ...
Franco Origlia / Contributor / Getty Images Catalent shares jumped on positive comments about its business. The company said it still needs more time to complete its fiscal Q3 earnings report.
Catalent shares rose 17% to $37.50 after the contract drug manufacturer provided updates on 2023 guidance and its delayed 10-Q filing. The company expects fiscal 2023 sales of $4.25 billion to $4. ...
The logo of the Catalent plant is seen outside their location where millions of doses of the AstraZeneca coronavirus disease (COVID-19) vaccine were reportedly found in Anagni, Italy, March 24 ...
Struggling biotechnology specialist Catalent (NYSE:CTLT) popped significantly higher on Friday despite poor financial performances and prognostications. Nevertheless, management helped soothe ...
Catalent trimmed its annual revenue and net income forecasts. The contract drug manufacturer said the cuts were due to operational challenges. Catalent said it continues to add new customers. It ...
Contract drug manufacturer Catalent (ticker: CTLT) delivered more bad news on Friday, but investors shrugged it off, securing the stock a top place in the S&P 500. The company said it will again ...
Catalent Inc. shares rose after the troubled contract drug manufacturer gave investors some reassurance about a slashed ...
Catalent's financials are still past due, but investors are looking forward. The pharmaceuticals contract manufacturer said Friday it is unable to file its financial results with the SEC for the ...
